Rights and permissions
About this article
Cite this article
Epirubicin favoured over doxorubicin in breast cancer. Pharmacoecon. Outcomes News 50, 5 (1996). https://doi.org/10.1007/BF03269815
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03269815